Invenomic Capital Management LP Raises Holdings in Helen of Troy Limited $HELE

by · The Markets Daily

Invenomic Capital Management LP increased its holdings in Helen of Troy Limited (NASDAQ:HELE – Free Report) by 6.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 593,310 shares of the company’s stock after buying an additional 38,325 shares during the quarter. Invenomic Capital Management LP’s holdings in Helen of Troy were worth $12,608,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of HELE. Envestnet Asset Management Inc. grew its holdings in Helen of Troy by 42.4% in the third quarter. Envestnet Asset Management Inc. now owns 195,657 shares of the company’s stock valued at $4,931,000 after purchasing an additional 58,214 shares during the period. Counterpoint Mutual Funds LLC grew its holdings in Helen of Troy by 882.6% in the third quarter. Counterpoint Mutual Funds LLC now owns 125,416 shares of the company’s stock valued at $3,160,000 after purchasing an additional 112,652 shares during the period. Seven Six Capital Management LLC acquired a new stake in Helen of Troy in the third quarter valued at approximately $1,378,000. Aster Capital Management DIFC Ltd acquired a new stake in Helen of Troy in the fourth quarter valued at approximately $504,000. Finally, Prescott Group Capital Management L.L.C. acquired a new stake in Helen of Troy in the fourth quarter valued at approximately $2,344,000.

Wall Street Analyst Weigh In

HELE has been the topic of several research analyst reports. Wall Street Zen lowered Helen of Troy from a “buy” rating to a “hold” rating in a report on Saturday, May 23rd. Zacks Research raised Helen of Troy from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 5th. Canaccord Genuity Group raised their price objective on Helen of Troy from $18.00 to $23.00 and gave the company a “hold” rating in a report on Friday, April 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Helen of Troy in a report on Friday, March 27th. Finally, UBS Group raised their price objective on Helen of Troy from $16.00 to $25.00 and gave the company a “neutral” rating in a report on Friday, April 24th. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Helen of Troy presently has an average rating of “Moderate Buy” and a consensus price target of $24.00.

Check Out Our Latest Research Report on HELE

Helen of Troy News Summary

Here are the key news stories impacting Helen of Troy this week:

  • Positive Sentiment: Helen of Troy was highlighted by Zacks as one of four cosmetics stocks benefiting from favorable industry trends, including stronger skincare demand, product innovation, and expanding digital channels. Article Title
  • Neutral Sentiment: Several law firms issued investor reminders and lead-plaintiff notices related to the already-filed class action against Helen of Troy, which mainly reinforces the lawsuit timeline rather than adding new business developments. Article Title
  • Negative Sentiment: The class-action filings allege misleading statements about operational health and distribution-center failures, creating a legal overhang that may keep pressure on HELE shares until the claims are resolved. Article Title

Helen of Troy Stock Performance

NASDAQ HELE opened at $26.47 on Thursday. The company has a market cap of $615.69 million, a PE ratio of -0.68 and a beta of 1.34. The stock’s 50 day simple moving average is $23.60 and its 200-day simple moving average is $20.11. Helen of Troy Limited has a 1-year low of $13.85 and a 1-year high of $33.73. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.71 and a quick ratio of 0.81.

Helen of Troy (NASDAQ:HELE – Get Free Report) last released its earnings results on Thursday, April 23rd. The company reported $0.83 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.09. The business had revenue of $470.03 million for the quarter, compared to the consensus estimate of $450.38 million. Helen of Troy had a positive return on equity of 7.00% and a negative net margin of 50.33%.The business’s quarterly revenue was down 3.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.33 earnings per share. Helen of Troy has set its FY 2027 guidance at 3.250-3.750 EPS. As a group, equities research analysts anticipate that Helen of Troy Limited will post 2.81 EPS for the current fiscal year.

Helen of Troy Company Profile

(Free Report)

Helen of Troy Limited is a global consumer products company that designs, sources and markets a diversified portfolio of household, health and beauty brands. Headquartered in El Paso, Texas, the company operates through three principal segments—Health & Home, Housewares and Beauty—offering products under well-known names including OXO, Vicks, Braun, Honeywell Home, PUR and Hot Tools. Helen of Troy distributes its products through a combination of mass, specialty and e-commerce channels to consumers, retailers and distributors worldwide.

The Housewares segment features kitchen tools, gadgets and organizational solutions marketed primarily under the OXO brand, recognized for its ergonomic “Good Grips” design.

Recommended Stories

Want to see what other hedge funds are holding HELE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Helen of Troy Limited (NASDAQ:HELE – Free Report).